AU589644B2

AU589644B2 - Method of preparing an extemporaneous homogeneous microcapsule suspension

Info

Publication number: AU589644B2
Application number: AU59031/86A
Authority: AU
Inventors: Massimo Calanchi; Leonardo Gentilini; Marco Marconi
Original assignee: Eurand International SpA; Eurand Italia SpA
Current assignee: Adare Pharmaceuticals SRL
Priority date: 1985-05-08
Filing date: 1986-05-02
Publication date: 1989-10-19
Anticipated expiration: 2006-05-02
Also published as: DK157730C; AU5903186A; ZA863399B; PT82541A; KR870700209A; DK7487D0; NZ216062A; KR900000212B1; NO171949B; DK157730B; FI86596B; WO1986006626A1; ATE59287T1; EP0222856B1; ES554777A0; RU2059409C1; PT82541B; FI865336A0; JPS62502859A; CA1274144A

Abstract

The invention relates to a method by which it is possible to prepare a formulation consisting of thickening or suspending agents and other excipients, having the property of dispersing and dissolving quickly in water or aqueous vehicles, without clot formation, with which it is possible to prepare an extermoraneous homogeneous suspension of solid particles and more particularly of micro-encapsulated drugs, which otherwise have the tendency to precipitate or float.

Description

"Method of preparing an extemporaneous homogeneous microcapsule suspension"

The present invention relates to a process for obtaining a pharmaceutical formulation, adapted to administer microcapsules of a drug in the form of a single dose bag, contents of which are poured in water at the moment of use.

In the description and claims the terms have the following meanings: "microcapsule" is used to indicate particles of drugs, powders, crystals, granules, pellets and also liquid droplets, coated with a polymeric membrane.

"microencapsulation" is generally the process used for applying the membrane.

"single dose bag" is a bag-like container for a single dose of active substance and the formulation excipients. "thickening or suspending agents" are water soluble substances varying density and viscosity so as to allow suspension of solid particles.

Microencapsulation is a well known process consisting in coating substances with a continuous film on the basis of natural or synthetic polymers.

There are several microencapsulation methods, and many of them and the corresponding patents are cited and described in the works "Microcapsules and Microencapsulation Techniques" (published in the year 1976) and "Microcapsules and other Capsules. Advance since 1975" (published in the year 1979) both by M.H. Gutcho. Among the preferred methods, those disclosed in U.S. Patent Nos. 3,196,827 and 3,253,944 to D.E. Wurster should be mentioned, relating to mecha- nical coating methods consisting in spraying the membrane around particles by means of suitable equipments, and those disclosed in U.S. Patents Nos. 3,415,758, 3,155,590 and 3,341,416, relating to chemical-physical coating methods based on coacervation or phase separation, where the membrane forming polymer is dissolved in a suitable solvent or microencapsulation vehicle and the substance to be dissolved is suspended in such a solution and kept under agitation. Coacervation of the polymer around the substance to be coated is obtained in several ways, for instance by temperature variation, addition of another polymer being more soluble in the vehicle_f addition of a non-solvent for the membrane forming polymer and so on. The membrane may be hardened and then microcapsules are separated from the vehicle e.g. by filtration or centrifugation and finally dried.

In the pharmaceutical field microencapsulation is used to obtain masking of unpleasant taste, to delay drug release, to prevent irritation given by contact of drugs with the gastrointestinal mucous membrane, to protect drugs from ambient decay, to separate drugs which are reactive to each other, to transform the drug into a form that can be used more readily, such as conversion from liquid condition into a powder comprised of microcapsules.

For administering microencapsulated drugs there are several dosage forms, such as capsules, tablets and also single dose bags which are particularly suitable for preparing formulations of granules and powders and therefore of microcapsules. This is also the most suitable or even the sole existing approach in case of administration of microcapsules for high dosage drugs.

Single dose bags containing microcapsules were already prepared in the past, sometimes even on an industrial scale, as mentioned in the manual "Microencapsu¬ lation" by J.R. Nixon, Chapter 7, page 93 but they have several drawbacks particularly due to hydrorepellency of polymers forming the microcapsule membra¬ ne, such as polymers based on cellulosic or wax-like substances, and to specific gravity of microencapsulated substances and therefore of said microcapsules. As a matter of fact, when the bag contents was poured as usually in water, milk or fruit juices, microcapsules precipitate to the glass bottom or floated on the liquid surface, sticking to the glass wall because of its hydrorepellancy. This entrained a considerable inaccuracy in the drug dosage is addition to a poor compliance of the patient, who could see floating particles or had a scraping feeling in the mouth and throat when swallowing the contents of the glass bottom, where was the mass of precipitated particles.

The addition to the formulation of thickening agents might delay or even eliminate microcapsule separation, but it gave particularly negative results, because in contact with water these substances are forming clots that are dissolved 5 slowly only under a vigorous mechanical agitation. An attempt was made to disperse these thickening substances together with the other formulation compo¬ nents by blending them in the conventional powder mixers, but even with such a measure, clot formation could not be prevented, but only partially reduced.

In order to solve these problems, Applicant effected thorough aimed experimen- ^■10 tal research so as to develop and perfect formulations for single dose bags which do not show the above mentioned drawbacks and make possible use of microcapsules in such a dosage form.

Thus it was found that it is possible to attain this object by mixing with the microcapsules granules in which the thickening agents are suitably dispersed by a 15 particular process being the subject matter of the present invention.

As already stated, microcapsules may be prepared with several systems. To be suitable for this purpose, it is also necessary that the drug coating membrane consists of a polymer approved for pharmaceutical use. Microcapsules are usually consisting of 3 to 50% by weight of polymer and 50 to 97% by weight of drug. The ^■--- membrane forming polymer should be permeable or soluble in the gastro-intestinal juices so as to allow drug release and absorption.

The preferred polymer used is ethylcellulose, but as non limiting illustrative examples other polymers may also be cited such as polyacrylates and polymet-ha- crylates, polyvinylchloride, polivinyl alcohol, polyethylene, polyamides, polysilo-

*^■•* xanes, cellulose acetophthalate, hydroxypropylmethylcellulose phthalate and also polymers of natural origin such as gelatin and gum arabic.

As to the drugs contained in the microcapsules, any pharmacologically active substance, either in the liquid or powdered, crystalline or granular form, may be coated with a polymeric membrane by using a suitable microencapsulation method.

-⁵⁰ Anyway as non limiting examples are hereby cited: potassium chloride, theophyl- line, aminophylline, acetylsalicylic acid, paracetamol, lithium sulphate, ibuprofen, cimetidine, dextromethorphane HBr, phenylpropanolamine HC1, noscapine HC1, phenylhephrine HCI, sodium dicloxacylline, sodium floxloxacilline, bacampicilline, methoclopramide, pseudohephedrine, organic and inorganic magnesium salts. The process being the subject matter of the present invention is now being disclosed. It allows to disperse the thickening substance among other components of the single dose bag and preferably but not exclusively in the sweetening agents, in such a way that when the contents of the single dose bags is poured in water or other aqueous medium, a rapid dissolution of the thickening agent is obtained, which will not only eliminate clot formation, but will also give to the medium a viscosity sufficient to keep microcapsules in a homogeneous suspension for a period of several minutes, even some tens of minutes, so as to avoid the above mentioned drawbacks, that it to say separation of microcapsules and assumption of wrong dosages. Said process substantially consits of the following steps:

(1) micronize, grind or anyway use the thickening agent with a grain size less than 100 mesh and preferably less than 200 mesh (Tyler);

(2) suspend this fine powder of thickening agent in a solution containing a binder; the thickening agent must be insoluble or anyway scarcely soluble in the solvent in which the binding agent is dissolved; this binder in its turn, besides being obviously soluble in the solvent, must also be water soluble, so as to bind the particles of thickening agent to the support described hereinbelow, but also to release them quickly once in contact with water;

(3) knead the suspension of the preceding point (2) with the granules or crystals of one or more components of the formulation to be filled in the single dose bag.

In a wet granulation kneader or mixer, such as a planetary kneader or a rotary pan, a counterrotating horizontal blade mixer or a vertical centrifugal batch mixer and the like, crystals or granules of one of the formulation components are placed.

To this end the sweetener or other water soluble excipient are preferably used, but mixtures of several formulation components may also be used. The thickener suspension is then slowly poured into the kneader in one or more stage. Contents are then mixed so as to obtain a homogeneous distribution of the suspension around the granules or crystals of the solid excipient or excipients. (4) The product so obtained is dried in oven or fluidized bed. The solvent evaporates and the thickener particles will remain stuck and homogeneously dispersed around the granule or crystals of solid excipients. The product obtained is finally sifted.

As thickening substances that may be used, the following non limiting illustrati¬ ve examples may be cited: alginates, carrageenan, agar-agar, tragacanth gum, xanthan gum, gum guar, carob gum, karaya gum, modified starch, carboxymethyl- cellulose, crystalline cellulose alone or in combination with other hydrocolloids (AVICEL RC-591 of FMC Corporation).

As binders which are soluble both in water and soluble solvents, the following illustrative and non limiting examples are cited: methylcellulose, hydroxypropyl- methylcellulose, hydroxybutylmethylcεllulose, hydroxyethylcellulose, hydroxy- propylcellulose, polyethyleneglycols, polyvinyl alcohols, polivinylpyrrolidone.

As inert excipients which are commonly part of the composition of single dose bags, and on which the thickener coating suspension may be applied, the following illustrative and non limiting examples are cited sucrose, lactose, levulose, man- nitol, dry sorbitol, maltodextrines, glycocoll, alanine, pentaerythrite.

In order to facilitate dissolution of the suspending agent a surfactant may be added to the formulation, such as dioctyl sodium sulphosuccinate, sodium laurylsul- phate, several sorbitol and sorbitane esters with fatty acids and so forth, which in some cases may accelerate dissolution in water of the suspending agent since its wettability is made easier.

The surfactant may be added in any stage of the process, even if it is preferable to add it in the stage (2) of the above described process, suspending it together with the thickening agent, or to mix it with the other excipients which are filled in the single dose bag.

The bags may be made with several materials, but the preferred one is aluminium foil laminated with a heat weldable plastic film as it givesbetter waterproofing results.

The single dose bags are filled with a suitable apparatus using a loading tower in which the mixture of drug microcapsules of the product prepared with the above process and of the other excipients required for the final formulation such as flavouring and dyeing agents, are placed. However, for a better dosage precision, equipments with two loading towers are preferably used, from which the drug microcapsules and the granulate proposed with the foregoing process, blended with other possible formulation excipients, are separately filled in the bags. The following examples of application should be construed as merely illustrative of the process of the present invention, but without any intention to limit the object and the scope of the invention.

EXAMPLE 1

(A) Preparation of microcapsules In a two liter beaker 1000 g of cyclohexane were placed. Under agitation 20 g ethylcellulose, 15 g polyethylene and 100 g potassium chloride crystals were added. The polymers were dissolved by heating to 78°C. Coacervation of ethylcellulose was obtained by cooling and ethylcellulose was deposited around the crystals of potassium chloride. Microcapsules were separated by filtration and dried in an oven with forced air circulation.

(B) Preparation of the suspending granulate

25 g Xanthan gum, having a grain size less than 200 mesh (Tyler) were suspended in 77.2 g of 3% solution of hydroxypropylcellulose in ethyl alcohol. In a horizontal blade mixer 492 g of sucrose crystals were placed. The suspension of Xanthan gum was slowly added in 15 minutes and the mixer was kept going for further 30 minutes. The product was dried in an oven with forced air circulation and sifted with an 850 microns sieve.

(C) Preparation of single dose bags

The suspending granulate (B) was mixed for 10 minutes in a cube mixer with 7.5 g citric acid and 7.5 g orange flavouring. 5.140 g of this mixture and 0.860 g of potassium chloride microcapsules, equivalent to 10 mEq potassium, were filled in each single dose bag.

EXAMPLE 2 (A) Microcapsules were prepared with the same process disclosed in Example 1. (B) following the process disclosed in Example 1, 850 g of granulate containing Xanthan gum as thickener, were prepared.

(C) Granulate (B) was mixed in a cube mixer for 15 minutes with 150 g of anhy¬ drous citric acid and 150 g of an orange flavouring different from that used in Example 1. Bags were then prepared using 10.5 of this mixture and 3.5 g of potassium chloride microcapsules, equivalent to 40 mEq of potassium.

EXAMPLE 3

(A) Microcapsules were prepared with the same process disclosed in Example 1.

(B) Same process and components of Example 1.

(C) 850 g of suspending granulate (A) were mixed in a cube mixer for 15 minutes with 50 g of citric acid and 150 g of orange flavouring of the same type used in

Example 2. Bags were then prepared using 8.5 g of this mixture, that is a quantity less than Example 2, and 3.5 g of potassium chloride microcapsules equivalent to 40 mEq of potassium.

EXAMPLE 4 Bags prepared in the preceding examples differ from each other for the quantity of thickening agent and of microcapsules and therefore for the potassium dosage. Tests were effected to check that a homogeneous suspension is obtained, after having poured into water and stirred for one minute the contents of each bag, and that this suspension is stable for about two hours. The details and remarks are shown in the table. Example Bag K Dose Water Agitation Suspension stability

N° Weight mEq ml sec

15 30 60 120 min min min min

1 6 10 50 60 good good good sufficient

2 14 40 200 60 good good good sufficient

3 12 40 200 60 good good good sufficient

EXAMPLE 5 From the suspension prepared in Example 4 samples were taken at different times in order to find analytically the amount of potassium release from microca¬ psules. The values found are reported in the following table, in which there are also the details of the release analysis od the same KCl microcapsules, placed alone in the same conditions of the bags, as well as of the KCl microcapsules analyzed with the rotating blade method described in U.S.P., XXI Edition, page 1244.

Example Condition microcapsule release N°

15 30 60 120 mm. min. min. min.

1 10 mEq/50 cc 0.0240.24 0.67 1.36 2 40 mEq/200 cc 0,13 1.88 4.75 10.2 3 40 mEq/200 cc 0,15 1.95 5.0 11.1

only KCL as Example 1 0.076 0.23 0.86 2.47 microcapsules as Ex. 2 and 3 0.55 1.87 5.0 10.9 USP 10.1 22.0 43.2 EXAMPLE 6

(A) The bitter taste of ibuprofen was masked by the following microencapsulation process: in a beaker with agitator 20 g gelatine, 20 g gum arabic and 1160 g of deionized water were added and heated up to 50°C so as to obtain a solution in which 400 g of ibuprofen crystals with a grain size less than 500 microns were suspended. Solution pH was brought to a value between 4 and 6 and then slowly cooled up to 15°C. The membrane deposited in this stage around the ibuprofen crystals was hardened with 10 g of 25% glutaric aldehyde in water. Three washings of microcapsules with deionized water were effected by stopping agitation and separating liquid from microcapsules by decantation. Microcapsules were filtered and dried in a fluidized bed by adding 20 g of highly dispersed silica to make drying easier. The obtained microcapsules were sifted through a 600 microns sieve.

(B) The suspending granulate was prepared as described in Example 1.

(C) 520 g of granulate (B) were mixed for 15 minutes in a cube mixer with 7.5 g of citric acid and 7.5 g of orange flavouring. The single dose bags so prepared each contain 5.530 g of this mixture and 0.470 g of ibuprofen microcapsules equivalent to a dosage of 400 mg of active substance. When the bag contents is poured in 50 ml of water and is stirred for 60 seconds, a homogeneous suspension of microcapsu¬ les stable up to 2 hours is obtained. EXAMPLE 7

(A) With a process similar to that disclosed in Example 1, a theophylline granulate with a grain size less than 500 microns was microencapsulated. By applying 6.3% of membrane microcapsules were obtained which in vitro slowly release theophylline in a time interval of 8 hours. (B) 125 g of sodium alginate with grain size less than 150 mesh (Tyler) were suspended in 385 ml of a 3% solution of hydroxypropylcellulose in ethyl alcohol. This suspension is added in counterrotating horizontal blade mixer in which 2500 g of granular sorbitol were placed. Addition is effected in four stages at an interval of 15-20 minutes from each other. After having dried in a fluidized bed the product is sifted through an 850 microns sieve.

(C) 800 g of suspending granulate (B) were mixed in a cube mixer for 15 minutes with 40 g of citric acid and 130 g of the orange flavouring used in Example 2. Bags were then prepared using 9.680 g of this mixture and 0.320 g of theophylline microcapsules equivalent to a dosage of 300 mg of theophylline. Contents of a bag was poured in about 100 ml of water and mixed with a teaspoon for 60 seconds. A homogeneous dispersion of the microcapsules is obtained, which is stable for about 2 hours.

EXAMPLE 8 (A) With a process similar to that of Example 1 paracetamol crystals were microencapsulated, with a grain size less than 500 microns, so as to mask its bitter taste. The obtained microcapsules have 4% of ethylcellulose membrane. (B) 100 g of sodium carrageenan, ground to a grain size a lower than 200 mesh (Tyler) were suspended in 350 g of a 2% solution of polyvinylpyrrolidone in ethyl alcohol in which also 5 g of dioctyl sulphosuccinate were dissolved.

This suspension was added slowly to 2500 g of sucrose crystals placed in a planetary kneader. After drying in a fluidized bed the product was sifted through an 850 microns sieve.

(C) The granulate was mixed for 15 minutes in a cube mixer with 50 g of raspberry flavouring. Bags containing 9.584 g of this mixture and 0.416 g of paracetamol microcapsules were then prepared, corresponding to a dosage of 400 mg of active substance.

The contents of a bag was poured in 100 ml of water and was stirred with a teaspoon for two minutes, obtaining a homogeneous and stable suspension for about one and a half hour.

Claims

CLAIMS 1) Method of preparing a formulation consisting of thickening or suspending agents and other excipients, having the property of being dispersed and dissolved quickly in water or aqueous vehicles without clot formation, so as to keep in homogeneous suspension solid particles and more particularly drug microcapsules, characterized by the fact of comprising the following steps: (a) micronizing or grinding the thickening agent; (b) suspending the thickening agent in a solution of a suitable binder; (c) dispersing the suspension around particles of one or more components of the formulation; and (d) drying and sieving of the obtained product. 2) Method according to Claim 1, characterized by the fact that instead of step

(a), thickening or suspending agents are used, which are available on the market already having a grain size lower than 200 mesh or preferably lower than 100 mesh (Tyler).

3) Method according to Claim 1 or 2, characterized by the fact 'that the thickening agent must be insoluble or scarcely soluble in the solvent in which the binder is dissolved, which in its turn must be soluble in water and organic solvents.

4) Method according to Claim 1 or 2, characterized by the fact that the component around the particles of which the suspension is dispersed, is an inert excipient and more particularly a sweetener. 5) Method according to one or more of the preceding Claims, characterized by the fact that the thickening agent is chosen from the illustrative group comprising alginates, carrageenan, agar-agar, gum tragacanth, xanthan gum, gum guar, carob gum, karaya gum, modified corn starch, carboxymethylcellulose, crystalline cellu¬ lose alone or in combination with other hydrocoUoids (AVICEL RC-591 of FMC Corporation).

6) Method according to one or more of the preceding Claims, characterized by the fact that the binder soluble in water and organic solvents is chosen from the illustrative group comprising methylcellulose, hydroxypropylmethylcellulose, hydroxybutylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, polye- thyleneglycols, polyvinyl alcohols, polyvinylpyrrolidone. 7) Method according to one or more of the preceding Claims, characterized by the fact that the inert excipient is chosen from the illustrative group comprising sucrose, lactose, levulose, mannitol, dry sorbitol, maltodextrines, glycocoll, alani- ne, pentaerythrite. 8) Method according to Claim 5, characterized by the fact that xanthan gum used as a thickening agent is that known under the trade mark Keltrol.

9) Method according to one or more of the preceding Claims, characterized by the fact that a surfactant is added to the formulation, for accelerating wettability of the thickening agent. 10) Formulation prepared according to one or more of the preceding claims, when used in a single dose bags, for keeping in a homogeneous suspension drug particles, when the bag contents is poured into water or an aqueous base liquid. 11) Formulation according to Claim 10, characterized by the fact that the drug particles consist of drug microcapsules coated with a polymeric membrane. 12) Formulation according to Claim 11, characterized by the fact' that the microencapsulated drug is potassium chloride.